{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:02:45Z","timestamp":1786122165899,"version":"build-2736575974"},"reference-count":15,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,9]]},"abstract":"ABSTRACT<\/jats:title>\n \n Aims<\/jats:title>\n Semaglutide 2.4\u2009mg causes substantial weight loss, but its average effect on patient\u2010reported physical function requires interpretation against clinically meaningful thresholds and routine clinical expectations. This systematic review and meta\u2010analysis aimed to evaluate the effects of once\u2010weekly subcutaneous semaglutide 2.4\u2009mg on patient\u2010reported physical functioning and weight\u2010related quality\u2010of\u2010life outcomes in adults with overweight or obesity.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods<\/jats:title>\n \n In this prospectively registered systematic review and meta\u2010analysis, MEDLINE via PubMed, Embase via Elsevier\n Embase.com<\/jats:ext-link>\n , Cochrane CENTRAL, Scopus, and\n ClinicalTrials.gov<\/jats:ext-link>\n were searched for randomised placebo\u2010controlled trials of once\u2010weekly subcutaneous semaglutide 2.4\u2009mg in adults with overweight or obesity reporting SF\u201036v2 or IWQOL\u2010Lite\u2010CT outcomes. Four STEP trials, including 4182 participants, contributed SF\u201036v2 Physical Functioning data.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Semaglutide improved SF\u201036v2 Physical Functioning compared with placebo, with a mean difference of 1.71 points and a 95% confidence interval of 1.07 to 2.35; heterogeneity was moderate, with\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200952.8%. However, this estimate was below the 3.7\u2010point meaningful within\u2010patient change threshold. Two trials, including 2768 participants, reported IWQOL\u2010Lite\u2010CT outcomes. Effects were larger in participants without type 2 diabetes and smaller in participants with type 2 diabetes, and both remained below published thresholds.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The available randomised evidence comes from the semaglutide development programme. Semaglutide statistically improves patient\u2010reported outcomes, but average functional gains are modest and should be communicated cautiously.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.70992","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:36:21Z","timestamp":1781577381000},"page":"7684-7688","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta\u2010Analysis"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2963-7259","authenticated-orcid":false,"given":"Naseem","family":"Eisa","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism Community Health Partners Fresno California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5826-447X","authenticated-orcid":false,"given":"Mira","family":"Khoury","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Faculty of Medicine Damascus University Damascus Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15620"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12310"},{"key":"e_1_2_10_11_1","volume-title":"User's Manual for the SF\u201036v2 Health Survey","author":"Maruish M. E.","year":"2011"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1168291"},{"key":"e_1_2_10_13_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3","author":"Higgins J. P. T.","year":"2022"},{"key":"e_1_2_10_14_1","article-title":"Glucagon\u2010Like Peptide\u20101 Receptor Agonists for the Treatment of Obesity","volume":"12","author":"Bracchiglione J.","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14551"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70992","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.70992","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:51:56Z","timestamp":1786092716000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.70992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/dom.70992"],"URL":"https:\/\/doi.org\/10.1111\/dom.70992","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70992\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70992\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70992\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70992\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70992\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"2026-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}